What is the mechanism of action of carbonic anhydrase inhibitors in glaucoma therapy?

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

What is the mechanism of action of carbonic anhydrase inhibitors in glaucoma therapy?

Explanation:
Carbonic anhydrase inhibitors reduce intraocular pressure by dampening the production of aqueous humor. They block carbonic anhydrase in the ciliary body, which normally converts CO2 and water into bicarbonate and protons. Bicarbonate is transported into the fluid that becomes aqueous humor, driving fluid secretion. When this enzyme is inhibited, bicarbonate formation drops, the active transport of ions and water into the anterior chamber decreases, and less aqueous humor is produced. The net effect is lower intraocular pressure. These agents (topical dorzolamide, brinzolamide; systemic acetazolamide) mainly reduce production rather than increase outflow, and they can have systemic or local side effects.

Carbonic anhydrase inhibitors reduce intraocular pressure by dampening the production of aqueous humor. They block carbonic anhydrase in the ciliary body, which normally converts CO2 and water into bicarbonate and protons. Bicarbonate is transported into the fluid that becomes aqueous humor, driving fluid secretion. When this enzyme is inhibited, bicarbonate formation drops, the active transport of ions and water into the anterior chamber decreases, and less aqueous humor is produced. The net effect is lower intraocular pressure. These agents (topical dorzolamide, brinzolamide; systemic acetazolamide) mainly reduce production rather than increase outflow, and they can have systemic or local side effects.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy